EA
ACRS icon

Emerald Acquisition’s Aclaris Therapeutics ACRS Stock Holding History

Emerald Acquisition’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$694K Hold
27,096
– – ﹤0.01% 2303
2016
Q2 		$500K Buy
+27,096
New +$537K ﹤0.01% 2469

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Emerald Acquisition's ACRS Position: Q3 2016 in Review

Emerald Acquisition held its Aclaris Therapeutics (ACRS) position steady in Q3 2016 at 27,096 shares worth $694K. The position accounts for ﹤0.01% of the portfolio, ranked #2303.

Emerald Acquisition first reported a position in ACRS in Q2 2016 and has held it in 2 quarters since. 58 funds tracked by Wall St. Rank hold ACRS as of Q3 2016.

  • Emerald Acquisition held 27,096 shares of Aclaris Therapeutics worth $694K as of Q3 2016.
  • Emerald Acquisition left its Aclaris Therapeutics share count unchanged in Q3 2016.
  • Aclaris Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2303 holding.
  • Emerald Acquisition first reported a position in Aclaris Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • 58 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.